ARCHIVES

Ilex Oncology Buys Symphar, Controls Drug For Bone Mets.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas

December 28, 2012

HOP Development Proceeding Guidelines For New, Revision Of Existing Control Grants Being Written

July 24, 1981

The March: AACR, AACI Compile List Of Activities Related To The March

May 8, 1998

Device Shortens Time To Make T Cells For Immunotherapy

March 27, 2009

NCI Health Disparities Center Will Attempt To Influence Policy, Harold Freeman Says.

November 3, 2000